Execellin

Execellin is a clinical-stage biotechnology company dedicated to developing a functional cure for Type 1 Diabetes (T1D). Founded by Dr. Denise Faustman of Massachusetts General Hospital, the company focuses on a dual-pronged approach to reverse the disease by resetting the immune system and replacing lost pancreatic function. Their lead program utilizes the BCG vaccine to induce tumor necrosis factor (TNF), which has been shown to selectively eliminate the autoreactive T-cells responsible for attacking insulin-producing islets. Additionally, Execellin is advancing an encapsulated cell therapy platform, often referred to as a bio-artificial pancreas, designed to provide a sustainable source of insulin without the need for systemic immunosuppression. The company's research aims to provide a long-term, insulin-independent solution for patients living with T1D.